Abstract
We have investigated the purging efficacy of positive selection of autologous mobilized CD34+ peripheral stem cells in 22 children with high-risk neuroblastoma. CD34+ cell selection was performed using the method of magnetic-activated cell sorting (MACS). The median purity of the CD34+ cells post selection was 97.6% (range 81.7–99.7). For detection of contaminating neuroblastoma cells before and after CD34+ selection, the chimeric anti-disialoganglioside GD2 antibody delta ch 14.18 was used. Prior to positive selection, various numbers of contaminating neuroblastoma cells were found in 17 patients. After positive CD34+ cell selection, low numbers of neuroblastoma cells were only detectable in four patients. In 18 patients, high-dose chemotherapy was performed and the isolated CD34+ cells were reinfused. In all patients, a rapid neutrophil recovery was seen with a median time to reach 0.5 × 109/l neutrophils of 12 days (range 8–24 days). Nine of the 18 patients are free of progression with a median follow-up of 55 months (range 45–70 months). Two patients are alive with relapse, six patients died due to progression or relapse and one patient died due to secondary AML 10 months after transplant while in remission from neuroblastoma. In summary, we show that, through a highly effective positive selection method, a high purging efficacy can be obtained without compromising the hematopoietic reconstitution capacity of the graft.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pritchard J, McElwain TJ, Graham-Pole J . High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma Br J Cancer 1982 45: 86 94
Moss TJ, Cairo M, Santana VM et al. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplanation Blood 1994 83: 3085 3089
Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells Blood 1994 84: 380 383
Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341: 85 86
Seeger RC, Vo DD, Ugelstad J, Reynolds CP . Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads Prog Clin Biol Res 1986 211: 285 293
Kremens B, Combaret V, Favrot MC et al. [Evaluation of a modified immunomagnetic procedure for the purging of neuroblastoma cells from bone marrow]. Evaluation eines modifizierten immunomagnetischen Verfahrens zur Entfernung von Neuroblastomzellen aus Knochenmark Monatsschr Kinderheilkd 1990 138: 331 336
Civin CI, Trischmann T, Kadan NS et al. Highly purified CD34-positive cells reconstitute hematopoiesis J Clin Oncol 1996 14: 2224 2233
Handgretinger R, Greil J, Schurmann U et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma J Hematother 1997 6: 235 242
Leung W, Chen AR, Klann RC et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma Bone Marrow Transplant 1998 22: 971 979
Miltenyi S . CD34+ selection: the basic component for graft engineering Oncologist 1997 2: 410 413
Lang P, Schumm M, Taylor G et al. Clinical scale isolation of highly purified peripheral CD34+ progenitors for autologous and allogeneic transplantation in children Bone Marrow Transplant 1999 24: 583 589
Handgretinger R, Lang P, Schumm M et al. Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting Bone Marrow Transplant 1998 21: 987 993
Schumm M, Lang P, Taylor G et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device J Hematother 1999 8: 209 218
Harmann O, Berthold F . Treatment of advanced neuroblastoma: the European experience In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma Elsevier: New York 2000 pp 437 452
Berthold F, Hero B . Neuroblastoma: current drug therapy recommendations as part of the total treatment approach Drugs 2000 59: 1261 1277
Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering J Hematother 1996 5: 213 226
Klingebiel T, Bader P, Bares R et al. Treatment of neuroblastoma stage 4 with 131l-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study Eur J Cancer 1998 34: 1398 1402
Handgretinger R, Anderson K, Lang P et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch 14.18 in patients with neuroblastoma Eur J Cancer 1995 31A: 261 267
Matthay KK . Neuroblastoma: biology and therapy Oncology 1997 11: 1857 1866
Lode HN, Handgretinger R, Schuermann U et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry Eur J Cancer 1997 33: 2024 2030
Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors Blood 1994 83: 636 640
Brenner MK, Rill DR . Gene marking to improve the outcome of autologous bone marrow transplantation J Hematother 1994 3: 33 36
Burchill SA, Lewis IJ, Abrams KR et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year J Clin Oncol 2001 19: 1795 1801
Benez A, Geiselhart A, Handgretinger R et al. Detection of circulating melanoma cells by immunomagnetic cell sorting J Clin Lab Anal 1999 13: 229 233
Damon LE, Rugo HS, Ries CA, Linker CA . Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia Bone Marrow Transplant 1996 17: 93 99
Ifversen M, Christensen LD, Rechnitzer C, Heilmann C . Monoclonal antibodies with neuroblastoma specificity: a flow cytometric analysis of cross-reactivity with CD34+ hematopoietic stem cells J Hematother Stem Cell Res 2000 9: 867 875
Handgretinger R, Schumm M, Lang P et al. Transplantation of megadoses of purified haploidentical stem cells Ann NY Acad Sci 1999 872: 351 361
Hafer R, Voigt A, Gruhn B, Zintl F . Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level J Neuroimmunol 1999 96: 201 206
Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells Blood 1997 90: 5002 5012
de Wynter EA, Buck D, Hart C et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors Stem Cells 1998 16: 387 396
Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group New Engl J Med 1999 341: 1165 1173
Cheung NK . Monoclonal antibody-based therapy for neuroblastoma Curr Oncol Rep 2000 2: 547 553
Acknowledgements
We thank Dr Wing Leung for helpful suggestions on the manuscript and Dr Stephen Gillies for providing the delta ch 14.18 antibody. This work was supported by a grant from the Deutsche Krebshilfe (W44/93/Ni6) and the Deutsche Leukaemieforschungshilfe (94.05).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Handgretinger, R., Lang, P., Ihm, K. et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 29, 731–736 (2002). https://doi.org/10.1038/sj.bmt.1703536
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703536
Keywords
This article is cited by
-
Label-free separation of neuroblastoma patient-derived xenograft (PDX) cells from hematopoietic progenitor cell products by acoustophoresis
Stem Cell Research & Therapy (2021)
-
Label-free neuroblastoma cell separation from hematopoietic progenitor cell products using acoustophoresis - towards cell processing of complex biological samples
Scientific Reports (2019)
-
Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor
Bone Marrow Transplantation (2006)
-
Hourly monitoring of circulating CD34+ cells to optimize timing of autologous apheresis in pediatric patients
Bone Marrow Transplantation (2005)
-
Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?
British Journal of Cancer (2003)